There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
|Articles|April 5, 2023
Self-Care for Psychiatric Clinicians
Author(s)Psychiatric Times Editors
Share your go-to methods for maintaining your mental and physical health in our Wellbeing Checkup video series.
Advertisement
Share the ways you prevent burnout and maintain your mental and physical health with Psychiatric Times® to be featured in an upcoming episode of
If you would like to discuss your healthy habits in an upcoming episode of Wellbeing Checkup, write us at
Advertisement
Related to this article
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
The New, Impending Adult ADHD Guidelines
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
5